Relmada Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M | $2.5M | $36.3M | $2.4M |
| Accounts Receivable | — | — | — | $512.4K | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $94.0M | $45.8M | $97.5M | $152.9M | $223.3M | $118.1M | $116.9M | $2.7M |
| Property, Plant & Equipment | — | — | — | — | — | $1.3K | $5.0K | $12.1K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M | $118.2M | $117.1M | $3.0M |
| Liabilities | ||||||||
| Accounts Payable | $1.6M | $4.1M | $3.5M | $5.3M | $11.2M | $8.3M | $522.7K | $765.4K |
| Total Current Liabilities | $6.4M | $10.3M | $12.2M | $12.5M | $15.1M | $12.6M | $1.5M | $5.9M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M | $12.6M | $1.5M | $8.6M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-698.3M | $-640.9M | $-560.9M | $-462.1M | $-305.1M | $-179.3M | $-119.9M | $-94.3M |
| Total Stockholders' Equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M | $105.6M | $115.7M | $1.4M |